PCSK9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing

A drug that works only helps if patients can actually get it. This study documented the access barriers that hobbled PCSK9 inhibitors after their launch — a problem of economics, not efficacy.

Examining over 9,000 prescriptions, the investigators found that fewer than half (47 percent) were approved by insurers, and that the strongest predictor of approval was not clinical need but payer type — Medicare and cash-paying patients fared far better than those with commercial insurance. Clinical factors mattered only modestly. Patients who clearly met the indication were frequently denied.

The finding is a vivid illustration of how cost and coverage policy, rather than medical evidence, often determine whether a proven therapy reaches the patient — a theme that connects to the broader health-system critiques in this library.

We rate the evidence strong for its descriptive purpose. It is a large, real-world analysis that reliably documents an access problem; it speaks to the economics and delivery of care rather than to clinical efficacy.